 Eli Lilly Co. LLY, 1.73 announced guidance for 2023 on Tuesday and highlighted potential launches for a series of treatments, including a potential regulatory submission for its much-anticipated obesity treatment tirzepatide. The company said it expects per-share earnings to range from 7.65 to 7.85, and adjusted EPS of 8.10 to 8.30. 